Nifty
Sensex
:
:
12113.45
41281.69
-61.20 (-0.50%)
-178.10 (-0.43%)

Pharmaceuticals & Drugs

Rating :
62/99  (View)

BSE: 500257 | NSE: LUPIN

717.65
14.25 (2.03%)
14-Feb-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  704.50
  •  721.45
  •  704.50
  •  703.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1845960
  •  13247.53
  •  884.00
  •  646.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,516.05
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 40,025.00
  • 0.70%
  • 2.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.93%
  • 0.98%
  • 10.92%
  • FII
  • DII
  • Others
  • 24.66%
  • 14.16%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 5.54
  • -1.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.35
  • -4.45
  • -8.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.32
  • -24.16
  • -38.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.54
  • 29.87
  • 24.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.39
  • 4.78
  • 2.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.76
  • 15.97
  • 12.96

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
3,769.27
4,504.87
-16.33%
4,359.65
3,951.06
10.34%
4,418.38
3,855.93
14.59%
4,406.32
4,033.83
9.23%
Expenses
3,340.17
3,752.33
-10.98%
3,628.62
3,401.42
6.68%
3,558.16
3,328.96
6.89%
3,534.03
3,325.08
6.28%
EBITDA
429.10
752.54
-42.98%
731.03
549.64
33.00%
860.22
526.97
63.24%
872.29
708.75
23.07%
EBIDTM
11.38%
16.70%
16.77%
13.91%
19.47%
13.67%
19.80%
17.57%
Other Income
93.59
43.42
115.55%
133.27
230.68
-42.23%
72.21
184.20
-60.80%
86.50
144.92
-40.31%
Interest
88.60
79.77
11.07%
86.46
73.82
17.12%
85.62
68.72
24.59%
85.52
58.53
46.11%
Depreciation
253.23
279.76
-9.48%
321.47
265.49
21.09%
317.09
258.98
22.44%
280.78
272.83
2.91%
PBT
-107.82
94.21
-
-90.11
441.01
-
529.72
383.47
38.14%
594.73
-942.04
-
Tax
767.02
247.80
209.53%
34.30
172.91
-80.16%
227.98
181.14
25.86%
299.84
-163.18
-
PAT
-874.84
-153.59
-
-124.41
268.10
-
301.74
202.33
49.13%
294.89
-778.86
-
PATM
-23.21%
-3.41%
-2.85%
6.79%
6.83%
5.25%
6.69%
-19.31%
EPS
-18.44
-3.35
-
-2.81
5.88
-
6.70
4.48
49.55%
6.40
-17.33
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,953.62
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
Net Sales Growth
3.72%
5.78%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
 
Cost Of Goods Sold
5,844.48
5,234.59
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
Gross Profit
11,109.14
11,483.59
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
GP Margin
65.53%
68.69%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
Total Expenditure
14,060.98
13,835.96
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
Power & Fuel Cost
-
475.51
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
% Of Sales
-
2.84%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
Employee Cost
-
3,151.29
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
% Of Sales
-
18.85%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
Manufacturing Exp.
-
2,030.42
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
% Of Sales
-
12.14%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
General & Admin Exp.
-
1,429.32
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
% Of Sales
-
8.55%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
Selling & Distn. Exp.
-
1,298.77
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
% Of Sales
-
7.77%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
Miscellaneous Exp.
-
216.06
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
446.97
% Of Sales
-
1.29%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
EBITDA
2,892.64
2,882.22
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
EBITDA Margin
17.06%
17.24%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
Other Income
385.57
364.02
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
Interest
346.20
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
Depreciation
1,172.57
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
PBT
926.52
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Tax
1,329.14
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
Tax Rate
143.46%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
PAT
-402.62
602.80
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
PAT before Minority Interest
-403.75
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
Minority Interest
-1.13
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
PAT Margin
-2.37%
3.61%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
PAT Growth
0.00%
143.32%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
 
Unadjusted EPS
-8.15
13.41
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
Share Capital
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
Total Reserves
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
Non-Current Liabilities
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
Secured Loans
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
Unsecured Loans
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
Long Term Provisions
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
Current Liabilities
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
Trade Payables
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
Other Current Liabilities
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
Short Term Borrowings
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
Short Term Provisions
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
Total Liabilities
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
Net Block
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
Gross Block
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
Accumulated Depreciation
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
Non Current Assets
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
Capital Work in Progress
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
Non Current Investment
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
Long Term Loans & Adv.
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
Other Non Current Assets
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
Current Assets
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
Current Investments
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
Inventories
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
Sundry Debtors
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
Cash & Bank
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
Other Current Assets
1,769.95
621.30
533.43
479.44
534.98
532.99
572.33
427.17
628.48
475.86
Short Term Loans & Adv.
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
Net Current Assets
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
Total Assets
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
PBT
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Adjustment
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
Changes in Working Capital
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
Cash after chg. in Working capital
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
Net Fixed Assets
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
Net Investments
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
Others
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
Cash from Financing Activity
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
Net Cash Inflow / Outflow
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
Opening Cash & Equivalents
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
Closing Cash & Equivalent
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
ROA
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
ROE
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
ROCE
8.48%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
Fixed Asset Turnover
1.95
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
Receivable days
65.46
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
Inventory Days
47.47
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
Payable days
59.26
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
Cash Conversion Cycle
53.67
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
Total Debt/Equity
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
Interest Cover
5.92
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71

News Update


  • Lupin launches Moxifloxacin Ophthalmic Solution
    14th Feb 2020, 16:37 PM

    The product would be manufactured at Lupin's Pithampur Unit II facility, India

    Read More
  • USFDA completes inspection of Lupin’s Pithampur facility
    12th Feb 2020, 15:12 PM

    The inspection for the Pithampur unit-1 facility closed with two 483 observations

    Read More
  • Lupin gets nod for Leflunomide Tablets
    6th Feb 2020, 09:06 AM

    The product would be manufactured at Lupin's Pithampur facility, India

    Read More
  • MHRA completes inspection at Lupin’s three manufacturing units in Pithampur
    27th Jan 2020, 09:55 AM

    The inspection for the three units at Pithampur closed with no critical observation and one major observation

    Read More
  • Lupin’s CSR arm wins Corporate Citizen award 2019
    21st Jan 2020, 10:37 AM

    The company was conferred this award in the CSR category 'Initiative towards Agriculture,' for its beekeeping project

    Read More
  • Lupin, EAU conclude third edition of Masterclass ‘Best of EAU19’
    20th Jan 2020, 10:11 AM

    It also marked the second consecutive year of Lupin’s collaboration with the EAU for organising the Masterclass

    Read More
  • USFDA completes inspection of Lupin’s Vizag API manufacturing facility
    18th Jan 2020, 11:01 AM

    The inspection was carried out between January 13, 2020 and January 17, 2020

    Read More
  • Lupin's Ankleshwar facility wins Par Excellence award
    13th Jan 2020, 10:16 AM

    The company’s nomination summarised its transformation project to improve the yield and quality of Cefadroxil products

    Read More
  • USFDA completes inspection of Lupin’s Nagpur facility
    13th Jan 2020, 09:47 AM

    The inspection closed with two 483 observations

    Read More
  • USFDA classifies inspection of Lupin’s Tarapur facility as OAI
    13th Jan 2020, 09:36 AM

    The inspection at the Toropur facility had closed with three observations

    Read More
  • Lupin's Ankleshwar facility wins gold award from American Society for Quality
    3rd Jan 2020, 10:20 AM

    This is the fourth consecutive year that Lupin's Ankleshwar facility has won the Gold Award from the American Society for Quality

    Read More
  • Lupin's Ankleshwar facility wins Frost & Sullivan's India Manufacturing Excellence awards
    24th Dec 2019, 16:15 PM

    The 2019 evaluation was done on the basis of organizations’ manufacturing capability, extended supply chain reliability and technology adoption

    Read More
  • Lupin receives USFDA’s nod for Betamethasone Dipropionate Ointment USP
    20th Dec 2019, 14:13 PM

    The product will be manufactured at company's Pithampur Unit 3 facility, India

    Read More
  • Lupin collaborates with American College of Gastroenterology
    20th Dec 2019, 10:51 AM

    Through this initiative, Lupin aims to bring in global educational material

    Read More
  • Lupin receives USFDA’s nod for Mycophenolic Acid Delayed-Release Tablets
    19th Dec 2019, 14:35 PM

    Mycophenolic Acid Delayed-Release Tablets had an annual sales of approximately $174 million in the US

    Read More
  • Lupin launches Doxercalciferol Injection
    19th Dec 2019, 14:04 PM

    Doxercalciferol Injection had an annual sale of approximately $132 million in the U.S.

    Read More
  • Lupin’s arm completes divestiture of Kyowa to Unison
    17th Dec 2019, 10:33 AM

    The divestiture which valued Kyowa at an Enterprise Value of JPY 57,361 million, was announced on November 11, 2019

    Read More
  • Lupin’s CSR arm wins award for ‘Excellence in Corporate Social Responsibility’
    3rd Dec 2019, 15:32 PM

    The company was conferred this award in the category for companies with turnover more than Rs 500 crore

    Read More
  • Lupin wins award for 'Operational Excellence in Manufacturing'
    3rd Dec 2019, 11:12 AM

    The company has won the prestigious award at the India Pharma Awards 2019

    Read More
  • Lupin launches Hydrocortisone Valerate Cream
    22nd Nov 2019, 15:13 PM

    Hydrocortisone Valerate Cream USP, 0.2%, had an annual sales of approximately $11.5 million in the U.S.

    Read More
  • Lupin launches ‘Adhero’ first-of-its-kind connected Smart Device in India
    22nd Nov 2019, 12:50 PM

    The new device, ADHERO, is designed to improve patient adherence to therapy

    Read More
  • Lupin launches generic KCI for Oral Solution
    19th Nov 2019, 14:51 PM

    Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately $90 million in the U.S.

    Read More
  • Lupin to divest entire stake in Kyowa Pharmaceutical
    12th Nov 2019, 09:10 AM

    The Board of Directors of the Company at its meeting held on November 11, 2019 has approved the same

    Read More
  • Lupin receives USFDA’s nod for Zileuton Extended-Release Tablets
    11th Nov 2019, 08:57 AM

    Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately $43 million in the US

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.